Your session is about to expire
← Back to Search
LY3484356 for Breast Cancer (EMBER Trial)
EMBER Trial Summary
This trial will test if a new drug is safe and effective for treating people with advanced breast or endometrial cancer.
EMBER Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEMBER Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EMBER Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can swallow pills.My brain or spinal cord cancer is stable.I do not have uncontrolled hepatitis, tuberculosis, or HIV.I have ER+/HER2- breast cancer and responded well to hormone therapy, or I have untreated advanced breast cancer.I am willing to provide samples of my previously collected tissue.My organs are functioning well.
- Group 1: Part D: Dose Expansion: LY3484356 +/- Abemaciclib
- Group 2: Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib
- Group 3: Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib
- Group 4: Dose Escalation LY3484356
- Group 5: Part B: Dose Expansion: Cohort E3: LY3484356
- Group 6: Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab
- Group 7: Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI
- Group 8: Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there any precedent regarding the use of LY3484356 in previous experiments?
"Currently, there are 387 active studies assessing the efficacy of LY3484356 with 85 being in Phase 3. Although Seattle, Washington is home to most clinical trials for LY3484356 , a total 23728 locations nationwide offers these research opportunities."
What adverse effects does LY3484356 pose for human health?
"Taking into account the current level of evidence, our experts evaluated LY3484356's safety at a 1 on the scale due to this being an early phase trial with limited data in regards to efficacy and risk."
Are there any available spots for participants in this exploration?
"Affirmative. Records available on clinicaltrials.gov suggest that this medical research is still recruiting patients, with the initial post dating back to December 10th 2019 and the last update taking place on November 23rd 2022. 500 individuals are sought from 49 distinct trial sites."
In what geographic areas can participants access this trial?
"The ongoing recruitment of participants for this trial is taking place at 49 diverse medical centres. These include sites in San Francisco, Portland and Jacksonville; there are also 46 other locations to choose from. Selecting the closest centre should help minimise any travel burdens if you opt into the study."
What is the capacity of this research project in terms of patient participants?
"To execute this trial, the sponsor - Eli Lilly and Company - needs to identify 500 eligible candidates. These research participants will be enrolled in locations such as Univ of California San Francisco (San Francisco) or OHSU Center for Health and Healing (Portland)."
What are LY3484356's primary therapeutic applications?
"LY3484356 can be utilised to treat transplant rejection, kidney disorders, Waldenström Macroglobulinemia and pulmonary conditions."
Share this study with friends
Copy Link
Messenger